SUMMARY The effects of 15, 30, 60 and 120 mg of isosorbide dinitrate (ISDN) on systolic blood pressure (SBP) and heart rate (HR) were compared after acute oral administration and during sustained therapy four times daily with ISDN in six patients. After any given dose, plasma ISDN levels were higher during sustained therapy than during acute therapy. NITRATES are often used to treat patients with angina pectoris and congestive heart failure. '-16 However, the development of tolerance during chronic therapy with these agents is of some concern. In animal experiments, the reduction in systemic arterial blood pressure induced by glyceryl trinitrate (GTN) is rapidly attenuated during continuous therapy with this agent.'7-26 Furthermore, in rats, the induction of tolerance was found to be time-and dose-dependent.23 Needleman and Johnson26 reported that all organic nitrates, especially erythrityl tetranitrate and mannitol hexanitrate, induced tolerance to the circulatory effects of GTN; isosorbide dinitrate (ISDN) induced the least tolerance.26 In contrast to the reports in animals, the observations regarding the development of tolerance during nitrate therapy in man have been conflicting. Many workers have reported that during continuous therapy with organic nitrates, the headaches disappeared or diminished in intensity,27-31 and tolerance to the circulatory effects and cross-tolerance to GTN were usually well established within a few weeks.29' 32 However, other workers have failed to
NITRATES are often used to treat patients with angina pectoris and congestive heart failure. '-16 However, the development of tolerance during chronic therapy with these agents is of some concern. In animal experiments, the reduction in systemic arterial blood pressure induced by glyceryl trinitrate (GTN) is rapidly attenuated during continuous therapy with this agent. '7-26 Furthermore, in rats, the induction of tolerance was found to be time-and dose-dependent.23 Needleman and Johnson26 reported that all organic nitrates, especially erythrityl tetranitrate and mannitol hexanitrate, induced tolerance to the circulatory effects of GTN; isosorbide dinitrate (ISDN) induced the least tolerance.26 In contrast to the reports in animals, the observations regarding the development of tolerance during nitrate therapy in man have been conflicting. Many workers have reported that during continuous therapy with organic nitrates, the headaches disappeared or diminished in intensity,27-31 and tolerance to the circulatory effects and cross-tolerance to GTN were usually well established within a few weeks.29' 32 However, other workers have failed to show the development of circulatory tolerance to ISDN and cross-tolerance to GTN during sustained therapy with ISDN.33-3 This controversy is unresolved.
The present investigation was designed 1) to study the phenomenon of circulatory tolerance during oral ISDN therapy and to determine how rapidly this tolerance develops during continuous therapy; 2) to determine whether the development of tolerance to ISDN therapy is related to its accelerated metabolism; and 3) to investigate the development of crosscirculatory tolerance to GTN during continuous ISDN therapy.
Methods
Fourteen patients (12 males and two females) constituted the study population. All had stable angina pectoris due to coronary artery disease. Their ages ranged from 42-70 years (average 56 years). None were hypertensive or had unstable angina or were in heart failure. None had taken long-acting nitrates in the past and none were taking medications at the time of the study. The study was explained to each patient and written informed consent obtained.
Circulatory Effects of Isosorbide Dinitrate
During Acute and Sustained Therapy This part of the investigation was designed to compare the effects of 15, 30, 60 and 120 mg of ISDN on systolic blood pressure (SBP) and heart rate (HR) after acute and sustained oral therapy. Six patients were studied. CIRCULATORY Sustained Therapy After completion of the acute studies the patients were treated with placebo four times daily for 7 days. On day 8, the studies were repeated before and 1, 2, 4 and 6 hours after the morning dose of placebo. ISDN 15 mg was then prescribed four times daily for 7 days. On day 15, the studies described above were repeated before and after the morning dose of 15 mg of ISDN. The dose of ISDN was doubled at weekly intervals to a maximum of 120 mg four times daily, but before each increment, the studies were repeated before and after the morning dose of the drug. Thus, each patient was studied before and after placebo, ISDN 15 mg, 30 mg, 60 mg and 120 mg over 5 weeks.
Measurements and Recordings
Modified lead V, was recorded at 1-minute intervals for 2 minutes in the supine and standing positions. The average values for the HR during 10 consecutive beats were measured from the ECG and the blood pressure was measured by sphygmomanometry at 1-minute intervals.
Venous blood (8 ml) was collected in tubes containing EDTA for determination of plasma ISDN concentration at 0, ½/2, 1, 2, 4 and 6 hours after the administration of drug or placebo on each day. The total blood loss was 440 ml over a period of 8 weeks. The plasma was immediately separated and stored at -20°C. Plasma ISDN was measured by a gas chromatographic method. This part of the investigation was designed to study the time required for the development of circulatory tolerance to ISDN during sustained therapy with this drug and to study the phenomenon of cross-tolerance to GTN. The drugs were prescribed at 6-hour intervals at specified times. Eight hospitalized patients were studied daily for 6 consecutive days after an overnight fast. The protocol described below is summarized in figure 1 .
Day 1
The HR and blood pressure were measured in the supine and standing positions at 0800 hours, after which a placebo tablet was administered. The HR and blood pressure were measured in supine and standing positions at 0830, 0900, 1000, 1200 and 1400 hours. The patients were given a light lunch at 1215 hours. At 1400 hours, 0.6 mg GTN was administered sublingually, and HR and blood pressure response were measured at 1, 2, 5, 10 and 15 minutes. After completion of these observations, placebo tablets were administered at 1430, 2000 and 0200 hours.
Blood samples were collected in tubes containing EDTA at 0800, 0830, 0900, 1000, 1200 Once tolerance was observed, the control observations at 0800 hours were made and 30 mg of ISDN was administered and its effects on HR and blood pressure studied over a 6-hour period. During the remainder of the day, three doses of ISDN (30 mg) were administered at 1400, 2000 and 0200 hours.
If tolerance to 30 mg of ISDN developed during the first day of therapy with this dose, studies were repeated the following day before and for 6 hours after the administration of 60 mg of ISDN. During the remainder of the day, three doses of ISDN (60 mg) were administered at 1400, 2000 and 0200 hours. The studies were repeated the following day before and for 6 hours after the administration of 60 mg of ISDN. Blood samples were obtained for determination of ISDN level at 0800, 0830, 0900, 1000, 1200 and 1400 hours. At 1400 hours, i.e., 6 hours after the 60-mg dose, 0.6 mg GTN was given sublingually and its effects on HR and blood pressure were recorded at l, 2, 5, 10 and 15 minutes. Blood samples for determination of GTN levels were collected at 1400, 1402, 1405 and 1410 hours.
Conventional statistical methods were used throughout. The changes in plasma ISDN concentration, HR and blood pressure were studied by analysis of variance, and the significance of the results was determined with the multiple range test.
Results

Circulatory Effects of Isosorbide Dinitrate During Acute and Sustained Therapy
Plasma Isosorbide Dinitrate Figure 2 shows the mean plasma concentration after each dose of ISDN after acute and sustained therapy. Plasma ISDN concentrations at any given dose of ISDN were significantly higher during sustained than during acute therapy (p < 0.01). 
Sustained Therapy
After therapy with 15 mg of ISDN four times daily for 7 days, SBP after the morning dose of 15 mg of CIRCULATION 528 of 60 and 120 mg of ISDN. These symptoms were associated with a fall in SBP to 70 mm Hg or less. The symptoms, however, disappeared promptly on assumption of the supine position. None of the patients had such symptoms during sustained therapy.
Development of Circulatory Tolerance to Isosorbide Dinitrate
The group values for HR and SBP in the supine and standing positions during placebo and ISDN treatment are shown in table 2. The HR and SBP did not change significantly during the 6-hour observation period after placebo. After the first dose of 15 mg of ISDN, SBP decreased significantly both in the supine and standing positions compared with the values after placebo (p < 0.01), and the effects persisted for 6 hours; the reduction in SBP was more pronounced in the standing position. After the first dose of ISDN, HR increased in both positions, but achieved statistical significance only in the standing position (p < 0.01) (fig. 4 ). After therapy with 15 mg of ISDN every 6 hours, attenuation of the fall in SBP was observed within 1 day in six patients and within 2 days in the remaining two patients. Thus, within 48 hours of therapy with 15 mg of ISDN every 6 hours, circulatory tolerance to this drug had developed in all patients. The group values for SBP were significantly lower after the first dose than after the fifth dose of 15 mg of ISDN (p < 0.01) (fig. 4) . Reduction in SBP was associated with an increase in HR after the first dose, but not after the fifth dose of 15 However, after regular treatment with ISDN for 5 days, 60 mg ISDN produced only a minimum reduction in SBP in both patients. This occurred despite the higher plasma ISDN levels after 60 mg of ISDN than after 15 mg of ISDN in both patients ( fig. 5 ).
Cross-tolerance to Glyceryl Trinitrate
The group values for HR and SBP in the supine and standing positions after the first dose of GTN during R.S. 4 6 TIME AFTER ORAL DOSE (hours) FIGURE 5 . Tolerance to the circulatory effects of isosorbide dinitrate (ISDN) during therapy with ISDN every 6 hours in patients RS and JF. After thefirst dose of 15 mg of ISDN, the fall in systolic blood pressure was greater in patient RS than in patient JF. After sustained therapy with ISDN for 5 days, the reduction in systolic blood pressure after a dose of60 mg was less than that after thefirst dose of ISDN (15 mg). Plasma ISDN concentrations after 60 mg of ISDN were higher than after 15 mg of ISDN. placebo therapy and after the second dose of GTN after 5 days of ISDN therapy are shown in table 3. The first dose of sublingual GTN (0.6 mg) while patients were on placebo produced a significant reduction in SBP and a rise in HR in the standing position within 2 minutes, and the effects persisted for 10 minutes ( fig. 6 ). Compared with the first dose effect of GTN, the reduction in SBP was markedly attenuated both in the supine (p < 0.05) and standing (p < 0.001) positions when the same dose of GTN (0.6 mg) was administered while patients were taking 60 mg of ISDN every 6 hours ( fig. 6) . Effects of the first dose of GTN on SBP varied widely from one subject to another. The data for two representative patients are shown in figure 7 , which shows that after the first dose of GTN, reduction in SBP was more marked in patient RS. However, when the second dose of GTN was given during regular ISDN therapy, the reduction in SBP was attenuated in both patients, even though plasma GTN levels were similar after the first and second dose of GTN ( fig. 7 ).
Adverse Effects
None of the patients experienced any side effects after placebo therapy. Three patients had lightheadedness associated with nausea in the upright position 1-2 hours after the first dose of ISDN (15 mg). Symptoms were associated with a SBP of 60 mm Hg or less but were relieved promptly when patients assumed the supine position. Postural hypotension and lightheadedness did not recur with subsequent doses of ISDN. Six of the eight patients had moderately severe headaches after the first dose of ISDN, but these became less pronounced with higher doses of ISDN in two patients and remained unchanged in four.
Discussion
The results have shown that after the same dose of ISDN, plasma concentrations were significantly higher during sustained than during acute therapy. However, the depressive effect on arterial pressure was markedly attenuated during sustained therapy. After therapy with 15 mg of ISDN every 6 hours, the circulatory effects of this drug were markedly attenuated within 24-48 hours in all patients. Furthermore, continuous therapy with ISDN reduced the depressive effect on arterial blood pressure of 0.6 mg of sublingual GTN.
In animal experiments, the phenomenon of circulatory tolerance to nitrates has been extensively studied. A 10-to 50-fold shift in the blood pressure/dose-response curve to GTN after repeated intravenous or subcutaneous administration of GTN for 4-7 days has been produced in dogs,20 24 rabbits'7 21 and rats.23 ' 26 The tolerance to the vasodepressor effects of GTN was dose-and time-related in rats. 23 Furthermore, Rush and co-workers24 were able to produce a decrease in the vasodepressor response to GTN in dogs by infusing 1 mg/kg of GTN over a period of 1 hour. In animals, development of tolerance was not unique to GTN and a similar phenomenon has tolerance, while ISDN induced the least tolerance.
In contrast to the reports in animals, observations of development of tolerance during nitrate therapy in man have been conflicting. The first report of circulatory tolerance to nitrates was described in 1888 in hypertensive patients who were receiving high doses of nitrates.27 In 1931, Crandell and co-workers29 reported that the repeated administration of erythrol tetranitrate, GTN, ethylene glycol dinitrate, methyl nitrate, and amyl nitrite led to the development of tolerance and cross-tolerance to the headache-producing action of these drugs. These workers did not provide information regarding the circulatory effects of these agents, but commented that the tolerance to the blood-pressure-lowering effects of these agents was not as easily established as was the tolerance to the headaches. 29 Similarly, tolerance to headaches induced by nitroglycerin in industrial workers has also been well documented.28 30 In a detailed study in 10 volunteers who were challenged with 0.3 mg sublingual GTN before and after daily therapy with pentaerythrol tetranitrate for 4 weeks, Schelling and Lasagna32 found that the reduction in blood pressure and increase in HR induced by GTN was markedly attenuated but not completely abolished after therapy with pentaerythrol tetranitrate. In the present study, the reduction in SBP FIGURE 6 . Cross-tolerance to the circulatory effects of glyceryl trinitrate (GTN) during therapy with isosorbide dinitrate (ISDN) every 6 hours (eight patients). Data represent mean + SEM. The first dose of 0.6 mg of GTN given 6 hours after placebo produced a more marked reduction in systolic blood pressure (p < 0.001) and a greater increase in heart rate (p < 0.05) than the second dose of0.6 mg ofG TN given 6 hours after a dose of 60 mg of ISDN after daily (ISDN) therapy every 6 hours for 5 days. Cross-tolerance to the circulatory effects of glyceryl trinitrate (GTN) during sustained isosorbide dinitrate (ISDN) therapy in patients RS and JF. After the first dose of GTN given 6 hours after placebo, the fall in systolic blood pressure was greater in patient RS. Despite similar plasma levels of GTN after thefirst and second dose of G TN, the reduction in systolic blood pressure was less after the second dose, which was administered 6 hours after a dose of60 mg of ISDN after daily ISDN therapy every 6 hours for 5 days.
induced by GTN was also markedly attenuated after therapy with ISDN every 6 hours for 5 days (fig. 6 ). On the other hand, Aronow and colleagues33 were unable to show the development of circulatory tolerance to 0.3 mg GTN during sustained therapy with sublingual ISDN. This discrepancy can best be explained by the differences in protocols.
In the present study, the reduction in SBP induced by the first dose of 15 mg of ISDN was markedly attenuated after regular therapy with ISDN every 6 hours for hours in all the patients. However, during sustained therapy, the circulatory tolerance was not complete and some reduction in SBP still occurred for up to 4 hours after the administration of single doses of ISDN (fig. 3) High plasma ISDN concentration and significant pharmacologic effects after oral ingestion of ISDN in the present study are in contrast to reports by Needleman and colleagues,38 who could not demonstrate a vasodepressor response to nitrates administered orally or into the portal vein of rats. However, these workers23' 26 and others25 have clearly shown that in animals, tolerance to the vasodepressor effects of nitrates administered intravenously or subcutaneously develops rapidly at the level of the vascular smooth muscle and is not due to the biotransformation of nitrates. Our results suggest a similar mechanism in man. Needleman and Johnson26 proposed that the circulatory tolerance to organic nitrates involves the oxidation of a critical sulphydryl group in the "glyceryl trinitrate receptor." This hypothesis is supported by the reversal of in vivo and in vitro tolerance induced by the disulphide-reducing agent dithiothreitol. 26 The efficacy of nitrates in angina pectoris and heart failure is in part due to their ability to reduce arteriolar and venous tone,39 which in turn leads to a reduction in ventricular volume at rest and during exrcise.40' 41 However, the rapid development of partial tolerance to the depressive effect on SBP of ISDN during continuous therapy and cross-circulatory tolerance to GTN documented in the present and a previous report32 and attenuation of venodilator response to GTN during continuous therapy with ISDN42 is of some concern. The rapid hemodynamic and clinical tachyphylaxis to the afterload-reducing agent prazosin was recently reported in patients with heart failure.43 Theoretically, the therapeutic efficacy of nitrates would also be expected to diminish during chronic therapy if the peripheral effects of these agents were in any way related to their therapeutic effects. However, this has not been borne out in clinical practice, as the persistance of therapeutic efficacy of ISDN and GTN during continuous therapy with ISDN has been well documented in patients with angina pectoris' 35 and heart failure.'0' 44 Therefore, the peripheral effects of nitrates, although attenuated during chronic therapy, as shown in the present and previous reports,32 ' 42 probably still play an important role in the maintenance of their therapeutic efficacy in angina pectoris and heart failure.
